Japanese Circulation Journal Vol. 65 , June 2001 and after the treatment with troglitazone or glibenclamide. For estimation of insulin sensitivity, the homeostasis model insulin resistance index (HOMA-R) (FPG×IRI/22.5) was calculated. 22, 23 ATP-stress 201 Tl myocardial scintigraphy was conducted before and after the treatments. The protocol of the study was approved by the Investigational Review Board of the hospital, and the study was conducted in compliance with the Helsinki Declaration. All subjects gave informed consent before enrollment into the study.
Echocardiography
Left ventricular wall thickness and dimensions, and left ventricular mass were calculated from 2-dimensional echocardiograms using a previous described algorithm, according to the recommendations of the American Society of Echocardiography. 24 Left ventricular ejection fraction was also calculated according to the American Society of Echocardiography criteria by the area -length method. 25 
ATP-Stress Thallium-201 Myocardial Scintigraphy
The details of the procedure have been described previously. 17 ATP was infused for 3 min through a peripheral venous catheter for 5 min at the rate of 0.16 mg·kg -1 ·min -1 . Next, 111 MBq (3 mCi) of 201 Tl were injected as a bolus into another venous site, and the infusion of ATP was continued for an additional 2 min. 201 Tl imaging was performed using a large field of view rotating gamma camera equipped with a low-energy, high-resolution collimator interfaced to a computer (Toshiba GMS-550U, Tokyo Japan). Tomographic reconstruction at 7 min (initial image) and 4 h (delayed image) after 201 Tl injection was performed and quantified by computerized 2-dimensional polar (Bull's eye) maps of radionuclide activity. The myocardial washout rate was defined as the percent change in activity from the initial to the delayed images within the left ventricle and calculated as: washout rate (%) = (A-B)/A×100, where A = average count/pixel in the left ventricle on the initial image and B = average count/pixel in same region on the delayed image. Because the initial 201 Tl distribution reflects a relative rather than an absolute reduction in myocardial blood flow, no myocardial abnormality was seen in diabetic patients in this study, all of whom may have homogeneous underperfusion of all myocardial regions. The myocardial washout rate has been analyzed in a nonrelative fashion to indicate diffuse hypoperfused myocardium that shows no perfusion defects. [19] [20] [21] 26 We evaluated the relationship between the myocardial washout rate and coronary flow reserve in the study patients within 2 weeks before randomization. According to our previous report, 18 coronary flow reserve is obtained from the ratio of ATP-induced (intravenous infusion at rate of 0.16 mg·kg -1 ·min -1 ) hyperemic to baseline time-averaged peak velocity, and as shown in Fig1, a significant relation was observed (r=0.71, p<0.01). Therefore, washout rate was used as the non-invasive evaluation of coronary circulation.
Statistical Analysis
Data are expressed as mean ± SEM. Differences between 2 groups were assessed by paired t test with 2 tails, and those among groups were assessed by analysis of variance followed by Bonferroni's test. Statistical significance of changes in FPG, IRI, hemoglobin (Hb) A1c, HOMA-R, and washout rate by the treatments were assessed by analysis of variance for repeated measures. Simple least-sequences regression analysis was used to assess the correlation between 2 variables. A value of p<0.05 was regarded as significant.
Results
Baseline Characteristics (Table 1) There were no significant differences in age, sex, heart rate, coronary risk factors other than DM, left ventricular mass index, and ejection fraction among the 3 groups, and no difference in body mass index, FPG, and HbA1c were recognized between the diabetic groups.
Changes in FPG, HbA1c, IRI, and HOMA-R
None of the patients were withdrawn during this study. The changes in FPG, HbA1c, and IRI are shown in Fig 2. Treatment with either troglitazone or glibenclamide for 3 months produced a similar reduction of FPG and HbA1c. IRI was not significantly but tended to be increased by glibenclamide, whereas it was decreased significantly by troglitazone. HOMA-R was also decreased significantly by troglitazone, but not by glibenclamide (Fig 3) .
Washout Rate in ATP-Stress Thallium-201 Myocardial Scintigram
Baseline washout rates were 42±5% in controls, 30±4%
in the troglitazone-treated group and 32±4% in the glibenclamide-treated group. The diabetic patient groups showed significantly lower washout rates than the control group. Heart rate, blood pressure, ejection fraction and serum creatinine were unchanged by the treatments in the diabetic groups. Fig 4 shows the washout rates before and 3 months after the drug treatments. In the troglitazone group, the washout rate was significantly improved, but not in the glibenclamide group. As shown in Fig 5, the increase in washout rate at the end-point of treatment from baseline correlated significantly with the decrease in HOMA-R.
Discussion
The present study demonstrated that troglitazone improved coronary circulation in the patients with NIDDM with insulin resistance and the improvement in washout rate correlated with a decrease of HOMA-R. Furthermore, glibenclamide did not improve the washout rate despite a similar reduction of FPG. This suggests that the beneficial effects of troglitazone on coronary circulation might be a result of improving insulin resistance rather than reducting the blood sugar level.
In the present diabetic patients, coronary microvascular disease may have been caused by hyperglycemia, as well as by hyperinsulinemia. Hyperglycemia induces advanced glycation end-products, activation of protein kinase C, and disturbance of the polyol metabolism pathway, resulting in oxidative stress in vascular vessel walls. [27] [28] [29] The enhanced cellular oxidative stress reduces nitric oxide and activates nuclear factor-b in endothelial cells, 30, 31 which may stimulate proliferation of vascular smooth muscle cells and increase vasotonus, so-called vascular remodeling. The intensive management of hyperglycemia prevents the development and progression of cardiovascular complications in insulin-dependent DM in report of the DCCT study, 32 and Yokoyama et al also reported that blood glucose concentration rather than insulin resistance was the main cause of the reduced coronary flow reserve in NIDDM patients. 33 However, in their study, treatment with sulfonylurea did not improve coronary circulation despite an adequate reduction in FPG and a decrease in HbA1c, for reasons that are unclear, although there are 2 possible causes. One cause might be the pharmacological action of sulfonylurea itself. Sulfonylurea, while promoting the release of insulin through a blockade of the metabolism-regulated ATP-sensitive potassium channels present in pancreas B-cell membranes, also blocks those channels present in coronary vasculature, [34] [35] [36] an action that might prevent coronary vasodilation in response to ATP infusion. Another cause might be the hyperinsulinemia invoked by sulfonylurea. Endogeneous hyperinsulinemia inhibits constitutive nitric oxide synthase and increase free radicals through the activation of NADH/NADPH oxidase activity, resulting in decreased nitric oxide in endothelium. 37 Thus, sulfonylurea might impair endothelium-dependent vasodilation and promote vascular remodeling.
Troglitazone is a newly developed antidiabetic agent that reduces insulin resistance. As confirmed in previous reports, troglitazone decreased blood sugar and plasma insulin level in the present study. In addition, troglitazone improved the washout rate in ATP-stress scintigraphy and the improvement correlated with a decrease in the plasma insulin level. This suggests that triglitazone might improve coronary microvessel disease by improving insulin resistance. Insulin promotes vascular hypertrophy and increases vascular tonus, so troglitazone may restore coronary circulation through the improvement of vasomotor functions by reducing the plasma glucose level as well as the plasma insulin level.
In conclusion, troglitazone may improve coronary circulation and prevent cardiovascular complication effectively in patients with NIDDM.
